Welcome to our dedicated page for Scinai Immunotherapeutics Ltd. SEC filings (Ticker: SCNI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Scinai Immunotherapeutics Ltd. filings document foreign private issuer reporting for a Nasdaq-listed ADS issuer operating biopharmaceutical R&D and CDMO businesses. Form 6-K reports furnish current information on material agreements, clinical and regulatory disclosures for PC111 and related immunology programs, Nasdaq minimum bid price notices, capital-structure matters, and incorporation of current reports into Form F-3 and Form S-8 registration statements.
The filing record also documents the completed acquisition of Recipharm Israel Ltd., renamed Scinai Biopharma Services Ltd., including audited subsidiary financial statements and unaudited pro forma consolidated and combined financial information. Proxy and governance filings cover annual general meeting materials, ADS voting procedures, board composition changes, auditor selection, risk factors, and shareholder voting matters.
Scinai Immunotherapeutics Ltd. entered into a private placement and warrant inducement financing expected to close on or about April 27, 2026, raising approximately $2.61 million in aggregate gross proceeds before fees and expenses.
The company agreed to sell 5,208,333 American Depositary Shares at $0.48 per ADS, together with Series A warrants to purchase up to 5,208,333 ADSs at $0.48 and Series B warrants to purchase up to 5,208,333 ADSs at $0.55. An existing investor also agreed to immediately exercise earlier warrants at $0.48 per ADS in exchange for new warrants to buy 458,621 ADSs at $0.55.
Scinai plans to use the net proceeds, along with existing cash, to expand its CDMO platform, advance customer programs and continue selective investment in its immunotherapy pipeline. Warrant exercises are subject to beneficial ownership limits of 4.99% or, if elected, 9.99% of voting power.
Scinai Immunotherapeutics files its annual report outlining severe financial stress and substantial doubt about its ability to continue as a going concern. As of December 31, 2025, cash and cash equivalents were $1.6 million against an accumulated deficit exceeding $120 million and continued operating losses.
The company runs both a contract development and manufacturing (CDMO) unit and early-stage NanoAb therapeutic programs, neither of which currently generates sufficient revenue. It highlights major execution, financing, regulatory, clinical, competitive and CDMO integration risks that could force it to cut activities or cease operations.
Scinai Immunotherapeutics Ltd. Chief Operating Officer Mark Elad has filed an initial ownership report showing a substantial equity position. He directly holds 160,355,016 Ordinary Shares, which include large restricted share unit (RSU) awards granted in January 2024 and November 2025 that vest over multiple years subject to continued service.
He also holds American Depositary Shares representing 13,460,984 underlying Ordinary Shares, convertible at any time with no expiration date. The filing records holdings only and does not report any recent share purchases or sales.
Scinai Immunotherapeutics has signed a Second Amendment to its Binding Option Agreement to acquire PinCell and aligned the option timelines with a European grant process. The deadline to meet option conditions is now August 31, 2026, with an exercise period through September 30, 2026.
Scinai also submitted a revised application to the FENG SMART Path program seeking €12 million in non-dilutive, non‑repayable funding to co-finance a €15 million R&D program for PC111, targeting severe autoimmune skin diseases. A funding decision is expected in about three to four months and, if awarded, could support early clinical development and human proof of concept while limiting shareholder dilution.
Scinai Immunotherapeutics Ltd. reported that it received a written notice from the Nasdaq Listing Qualifications Department on March 12, 2026 stating that its American Depositary Shares are not in compliance with the Nasdaq Capital Market’s minimum bid price requirement, because the closing bid price was below $1.00 for 30 consecutive business days.
The notice does not immediately affect the listing or trading of the ADSs. Scinai has 180 calendar days, until September 8, 2026, to regain compliance, which will occur if the closing bid price is at least $1.00 for a minimum of ten consecutive business days. The company plans to monitor its share price and evaluate options to regain compliance.
Scinai Immunotherapeutics Ltd. director Yael Margolin filed an initial ownership report showing existing equity interests rather than new trades. Margolin directly holds 50 American Depositary Shares, which are convertible at any time into 200,000 Ordinary Shares and have no expiration date.
In addition, Margolin holds stock options over 1,720,000 and 8,000,000 Ordinary Shares at an exercise price of $0.0050 per share, expiring on August 24, 2033, and options over 48,200,000 Ordinary Shares at an exercise price of $0.0004 per share, expiring on December 22, 2035. These options vest in annual installments beginning on August 24, 2024, August 24, 2027, and December 22, 2026, subject to continued service.
Scinai Immunotherapeutics Ltd. director Uri Ben-Or filed an initial ownership report showing substantial equity holdings. He directly beneficially owns 33,329,004 Ordinary Shares, including several large restricted share unit (RSU) grants that vest over multiple years, subject to his continued service. These include 4,425,004 Ordinary Shares in RSUs granted on January 25, 2024, 904,000 Ordinary Shares in RSUs granted on November 21, 2024, and 28,000,000 Ordinary Shares in RSUs granted on November 12, 2025, each with specified multi-year vesting schedules. He also holds 630 American Depositary Shares, which are convertible at any time into 2,519,344 Ordinary Shares with no expiration date.
Scinai Immunotherapeutics Ltd. director Samuel J. Moed filed an initial ownership report showing existing equity interests. He holds 50 American Depositary Shares convertible into 200,000 Ordinary Shares at any time with no expiration date, plus stock options over 4,000,000, 8,000,000 and 48,200,000 Ordinary Shares at exercise prices of $0.0050 and $0.0004 per share. These options vest in annual installments beginning on August 24, 2024, August 24, 2027 and December 22, 2026, contingent on his continued service, and expire between 2033 and 2035.
Scinai Immunotherapeutics Ltd. director Mark Germain reported his initial holdings of stock options in the company. He holds three option awards that together are exercisable for 11,628,400 Ordinary Shares at an exercise price of 0.0050 and 16,000,000 Ordinary Shares at an exercise price of 0.0050, both expiring on 2033-08-24, and 100,000,000 Ordinary Shares at an exercise price of 0.0004 expiring on 2035-12-22.
One option vests in a single installment on August 24, 2027, while the others vest in three equal annual installments starting August 24, 2024 and December 22, 2026, in each case conditioned on Mr. Germain’s continued service. The filing notes that the Ordinary Shares are represented by American Depositary Shares, each currently representing four thousand Ordinary Shares.
Scinai Immunotherapeutics Ltd. director Green Jay has reported initial holdings in connection with becoming an insider. The filing shows direct ownership of 50 American Depositary Shares, which are convertible at any time into 200,000 Ordinary Shares and have no expiration.
Green Jay also holds stock options over 1,000,000 Ordinary Shares and 8,000,000 Ordinary Shares at an exercise price of $0.0050 per share, expiring on August 24, 2033, plus options over 48,200,000 Ordinary Shares at an exercise price of $0.0004 per share, expiring on December 22, 2035. These options vest in installments between August 24, 2025 and December 22, 2027, subject to continued service.